GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.

Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA, Volevodz NN, Bowers CY

Clinical endocrinology1 Sept 1995Cited by 8 (Europe PMC)

PMID7586605DOI10.1111/j.1365-2265.1995.tb02042.xPepBankPUB-07586605

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy men, peak GH at 30 minutes was 109.7 mU/l after GHRP‑2 and 32.8 mU/l after GHRH1-29NH2.
In plain wordsIn healthy men, GHRP‑2 produced a higher peak growth hormone level at 30 minutes than GHRH1-29NH2.
Peptide
GHRP-2
Outcome
IncreasePeak GH at 30 minutes after GHRP-2
Study
n = 8
Comparator
GHRH1-29NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg BW · intravenousAs given in this study (human).
Measurements
Peak GH at 30 min
109.7 mU/l
GHRP-2
Peak GH at 30 min
32.8 mU/l
GHRH1-29NH2
Source sentences
Summary
Peak GH levels at 30 minutes were 32.8 +/- 27.3 (mean +/- SD), 109.7 +/- 56.1 and 140.9 +/- 80.6 mU/l, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects underwent three tests in a randomized order: (1) i.v. bolus of GHRH1-29NH2 (1 microgram/kg BW), (2) i.v. bolus of GHRP-2 (1 microgram/kg BW), (3) i.v. bolus of GHRH1-29NH2 combined with GHRP-2 (same dosages).
Summary · context
Eight healthy non-obese male volunteers, aged 25-34 years.
Report a problemFND-0758660501
02HumanRandomized controlled trialEfficacy outcome
In healthy men, the GH AUC over 90 minutes after GHRP‑2 was significantly higher than after GHRH1-29NH2 (P = 0.0003).
In plain wordsIn healthy men, GHRP‑2 released significantly more growth hormone over 90 minutes than GHRH1-29NH2 did.
Peptide
GHRP-2
Outcome
IncreaseGH AUC (90 min) after GHRP-2 versus GHRH1-29NH2
Study
n = 8
Comparator
GHRH1-29NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg BW · intravenousAs given in this study (human).
Measurements
GH AUC
6205.1 mU/lmin
GHRP-2
GH AUC
2061.2 mU/lmin
GHRH1-29NH2
Source sentences
Summary
The area under the curve for GH levels (GH AUC) calculated for the first 90 minutes after the GHRH1-29NH2 test (2061.2 +/- 1601.9 mU/lmin) was significantly lower than those after GHRP-2 (6205.1 +/- 3216.9 mU/lmin) and the combined GHRH1-29NH2 and GHRP-2 challenge (9788.3 +/- 5530.4 mU/lmin) (P = 0.…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects underwent three tests in a randomized order: (1) i.v. bolus of GHRH1-29NH2 (1 microgram/kg BW), (2) i.v. bolus of GHRP-2 (1 microgram/kg BW), (3) i.v. bolus of GHRH1-29NH2 combined with GHRP-2 (same dosages).
Summary · context
Eight healthy non-obese male volunteers, aged 25-34 years.
Report a problemFND-0758660502
03HumanRandomized controlled trialEfficacy outcome
In healthy men, the GH AUC over the first 90 minutes after combined GHRH1-29NH2 and GHRP‑2 was significantly higher than after GHRH1-29NH2 alone (P = 0.00005).
In plain wordsIn healthy men, GHRH1-29NH2 plus GHRP‑2 released more growth hormone over 90 minutes than GHRH1-29NH2 alone.
Peptide
GHRP-2
Outcome
IncreaseGH AUC after GHRH1-29NH2 plus GHRP-2 versus GHRH1-29NH2 alone
Study
n = 8
Comparator
GHRH1-29NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg BW · intravenousAs given in this study (human).
Measurements
GH AUC
9788.3 mU/lmin
combined GHRH1-29NH2 and GHRP-2
GH AUC
2061.2 mU/lmin
GHRH1-29NH2
Source sentences
Summary
The area under the curve for GH levels (GH AUC) calculated for the first 90 minutes after the GHRH1-29NH2 test (2061.2 +/- 1601.9 mU/lmin) was significantly lower than those after GHRP-2 (6205.1 +/- 3216.9 mU/lmin) and the combined GHRH1-29NH2 and GHRP-2 challenge (9788.3 +/- 5530.4 mU/lmin) (P = 0.…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects underwent three tests in a randomized order: (1) i.v. bolus of GHRH1-29NH2 (1 microgram/kg BW), (2) i.v. bolus of GHRP-2 (1 microgram/kg BW), (3) i.v. bolus of GHRH1-29NH2 combined with GHRP-2 (same dosages).
Summary · context
Eight healthy non-obese male volunteers, aged 25-34 years.
Report a problemFND-0758660505

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

04HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy men, the GH AUC of the combined GHRH1-29NH2 and GHRP‑2 test differed significantly from the GHRP‑2 test (P = 0.016).
In plain wordsIn healthy men, GHRH1-29NH2 plus GHRP‑2 gave a larger growth hormone response than GHRP‑2 alone.
Peptide
GHRP-2
Outcome
IncreaseGH AUC after GHRH+GHRP-2 versus GHRP-2 alone
Study
n = 8
Comparator
GHRP-2 alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
9788.3 mU/lmin
combined
GH AUC
6205.1 mU/lmin
GHRP-2
Source sentences
Summary
Although the GH AUC of the GHRP-2 test and the combined GHRH1-29NH2 and GHRP-2 test differed significantly (P = 0.016, t-test)
3 context sentences(design, population, supporting numbers)
Summary · context
The area under the curve for GH levels (GH AUC) calculated for the first 90 minutes after the GHRH1-29NH2 test (2061.2 +/- 1601.9 mU/lmin) was significantly lower than those after GHRP-2 (6205.1 +/- 3216.9 mU/lmin) and the combined GHRH1-29NH2 and GHRP-2 challenge (9788.3 +/- 5530.4 mU/lmin) (P = 0.…
Summary · context
Subjects underwent three tests in a randomized order: (1) i.v. bolus of GHRH1-29NH2 (1 microgram/kg BW), (2) i.v. bolus of GHRP-2 (1 microgram/kg BW), (3) i.v. bolus of GHRH1-29NH2 combined with GHRP-2 (same dosages).
Summary · context
Eight healthy non-obese male volunteers, aged 25-34 years.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-0758660503
05HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy men, the GH AUC after combined GHRH1-29NH2 and GHRP‑2 was not significantly different from the sum of the AUCs after the separate tests.
In plain wordsIn healthy men, giving GHRH1-29NH2 and GHRP‑2 together did not release more growth hormone than the two separate responses added up.
Peptide
GHRP-2
Outcome
No significant changeSynergy of GHRH1-29NH2 and GHRP-2 (combined AUC versus sum of separate AUCs)
Study
n = 8
Comparator
Sum of separate GH AUCs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
the latter was not significantly different from the sum of the GH AUCs of each subject after the separate tests.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects underwent three tests in a randomized order: (1) i.v. bolus of GHRH1-29NH2 (1 microgram/kg BW), (2) i.v. bolus of GHRP-2 (1 microgram/kg BW), (3) i.v. bolus of GHRH1-29NH2 combined with GHRP-2 (same dosages).
Summary · context
Eight healthy non-obese male volunteers, aged 25-34 years.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-0758660504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.